Table 1 Characteristics of patients according to proposed IrAE causality at ICU discharge (n = 110 patients)
From: ICU admission for solid cancer patients treated with immune checkpoint inhibitors
All n = 110 | Unlikely causality n = 66 (60) | Likely causality n = 44 (38) | P-value | |
|---|---|---|---|---|
Male sex | 73 (66) | 44 (67) | 29 (66) | 0.93 |
Age (years) | ||||
ECOG-PS (Miss. = 1) | 0.001 | |||
0 | 29 (27) | 12 (18) | 17 (39) | |
1 | 38 (35) | 20 (31) | 18 (41) | |
2 | 29 (27) | 22 (34) | 8 (16) | |
3 | 13 (12) | 11 (17) | 2 (5) | |
CCI | ||||
Chronic pulmonary disease | 32 (29) | 20 (30) | 12 (27) | 0.73 |
Type of cancer | 0.59 | |||
Lung | 74 (67) | 46 (70) | 28 (64) | |
Melanoma | 18 (16) | 8 (12) | 10 (23) | |
Bladder | 5 (5) | 4 (6) | 1 (2) | |
Kidney | 3 (3) | 2 (3) | 1 (2) | |
Other | 10 (9) | 6 (9) | 4 (9) | |
Metastatic disease | 89 (81) | 54 (82) | 35 (80) | 0.77 |
Brain metastasis | 80 (18) | 13 (20) | 7 (16) | 0.61 |
Cancer status | 0.22 | |||
Controlled | 40 (36) | 20 (30) | 20 (45) | |
In progression | 33 (30) | 23 (35) | 10 (23) | |
Not evaluated | 37 (34) | 23 (35) | 14 (32) | |
ICI characteristics | ||||
Line of treatment | 0.37 | |||
1 or 2 | 94 (85) | 58 (88) | 36 (82) | |
> 2 | 16 (15) | 8 (12) | 8 (18) | |
ICI | 0.16 | |||
Anti-PD-1/-L1 alone | 105 (95) | 65 (98) | 40 (91) | |
Combination with anti-CTLA4 | 5 (5) | 1 (2) | 4 (9) | |
History of irAE ≥ 2 before ICU admission | 24 (22) | 10 (15) | 14 (32) | 0.04 |
Time from first ICI infusion (months) | 71 (28–165) | 69 (19–144) | 78 (34–185) | 0.31 |